Our study will further investigate the impact of targeted therapies, including STING agonists, PARP inhibitors, and natural compounds, on tumor immune dynamics and treatment efficacy, ultimately providing insights into strategies for enhancing immunotherapeutic responses and overcoming resistance in these cancers. The gene discussed is STING1; the disease is cancer.